Erez Chimovits - 07 Aug 2026 Form 4 Insider Report for Braveheart Bio, Inc. (BRVE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BRVE
Reported as of: 07 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2026, 17:31:57 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Erez Chimovits

Key filing fact

Erez Chimovits filed Form 4 for Braveheart Bio, Inc. (BRVE) on 11 Aug 2026.

Key facts

This page summarizes Erez Chimovits's Form 4 filing for Braveheart Bio, Inc. (BRVE).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2026, 17:31.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001706399 Primary reporting owner

Chimovits Erez

Relationship: Director, 10%+ Owner
Address: C/O BRAVEHEART BIO, INC., ONE LETTERMAN DR., BLDG. A, STE. A4-300, SAN FRANCISCO
Signature: /s/ Erez Chimovits
Signature date: 11 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BRVE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +9,132,420
Change %: +828%
Price
Shares after: 10,235,159
Date: 07 Aug 2026
Ownership: See footnotes
Footnotes: F1, F3, F5

BRVE transaction

Common Stock

Purchase

Transaction value
Shares: +1,666,667
Change %: +16%
Price: $18.00^*
Shares after: 11,901,826
Date: 07 Aug 2026
Ownership: See footnotes
Footnotes: F2, F3, F5

BRVE transaction

Common Stock

Purchase

Transaction value
Shares: +273,333
Change %
Price: $18.00^*
Shares after: 273,333
Date: 07 Aug 2026
Ownership: See footnotes
Footnotes: F2, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BRVE transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -40,000,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 07 Aug 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 9,132,420
Exercise price
Footnotes: F1, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.

Footnote F2

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Footnote F3

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Footnote F4

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis.

Footnote F5

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.